Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.
Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 342 of these are profiled in the report along with tabulation of 811 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2015 according to technologies, applications and geographical regions. Forecasts are made up to 2025. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
Benefits of this report:
- This report has evolved during the past 20 years, profiting from feedback by numerous readers and experts.
- The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
- Includes profiles of 343 companies, the largest number in any report on this topic.
- 600 references, cited in the report are included in the bibliography.
- The text is supplemented by 101 tables and 15 figures.
Key Topics Covered:
Part I: Technologies & Applications
Executive Summary
1. Introduction
2. Molecular Diagnostic Technologies
3. Biochips, Biosensors, and Nanobiotechnology
4. Proteomic Technologies for Molecular Diagnostics
5. Molecular Diagnosis of Genetic Disorders
6. Molecular diagnosis of cardiovascular disorders
7. Molecular Diagnosis of Infections
8. Molecular Diagnosis of Cancer
9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare
10. Molecular Diagnostics in Forensic Medicine and Biological Warfare
11. References
Part II: Regulations, Markets & Companies
12. Ethics, Patents and Regulatory issues
13. Markets for Molecular Diagnostics
14. Companies involved in molecular diagnostics
For more information about this report visit http://www.researchandmarkets.com/research/pqgfm8/molecular
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: In Vitro Diagnostics, Molecular Diagnostics


KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Apple Turns 50: From Garage Startup to AI Crossroads
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 



